Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.54 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.54 |
| ▸ | GLO1 | Q04760 | 5/20 | 0.48 |
| ▸ | LTA4H | P09960 | 2/20 | 0.38 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.36 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.36 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11867062 | 0.88 | PTGS1 (0.54) | PTGS1GSTK1GLO1LTA4HFOLH1 | |
| SCHEMBL11867085 | 0.88 | PTGS1 (0.54) | PTGS1GSTK1GLO1LTA4HFOLH1 | |
| SCHEMBL1683015 | 0.88 | GLO1 (0.45) | PTGS1GSTK1GLO1LTA4HFOLH1 | |
| SCHEMBL11874436 | 0.87 | GLO1 (0.59) | PTGS1GSTK1GLO1LTA4HFOLH1 | |
| SCHEMBL5000996 | 0.87 | GLO1 (0.59) | PTGS1GSTK1GLO1LTA4HFOLH1 | |
| SCHEMBL30249512 | 0.87 | PTGS1 (0.52) | PTGS1GSTK1GLO1FOLH1 | |
| SCHEMBL19492418 | 0.85 | PTGS1 (0.50) | PTGS1GSTK1GLO1 | |
| SCHEMBL11863989 | 0.83 | PTGS1 (0.53) | PTGS1GSTK1GLO1LTA4H | |
| SCHEMBL11863966 | 0.83 | PTGS1 (0.53) | PTGS1GSTK1GLO1LTA4H | |
| SCHEMBL21111836 | 0.83 | PTGS1 (0.53) | PTGS1GSTK1GLO1FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210254056-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-10877035-B2 | Advanced drug development and manufacturing | ICAGEN, LLC (US) | 2020-12-29 | — | — | US | disclosed |
| EP-2755707-B1 | INHALER | ASTRAZENECA AB (SE) | 2018-11-14 | — | — | EP | disclosed |
| WO-2018204764-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION (US) | 2018-11-08 | — | — | WO | disclosed |
| EP-3345644-A1 | INHALER | Astrazeneca AB (SE) | 2018-07-11 | — | — | EP | disclosed |
| EP-2755708-B1 | INHALER | ASTRAZENECA AB (SE) | 2018-05-09 | — | — | EP | disclosed |
| EP-2448623-B1 | DISPENSER AND METHOD FOR ENTRAINING POWDER IN AN AIRFLOW | ASTRAZENECA AB (SE) | 2017-12-20 | — | — | EP | disclosed |
| EP-2341968-B1 | A BREATH ACTIVATED INHALER | ASTRAZENECA AB (SE) | 2017-05-10 | — | — | EP | disclosed |
| EP-2334358-B1 | INHALATION DEVICE FOR DISPENSING MEDICAMENT | ASTRAZENECA AB (SE) | 2016-02-10 | — | — | EP | disclosed |
| US-20150309021-A1 | Advanced Drug Development and Manufacturing | LOS ALAMOS NATIONAL SECURITY, LLC | 2015-10-29 | — | — | US | disclosed |
| WO-2010042036-A1 | INHALER WITH AUDIBLE INDICATOR MEANS | ASTRAZENECA AB (SE) | 2010-04-15 | — | — | WO | disclosed |
| WO-2010042034-A1 | A BREATH ACTIVATED INHALER | ASTRAZENECA AB (SE) | 2010-04-15 | — | — | WO | disclosed |
| WO-2010042033-A1 | INHALATION DEVICE AND METHOD OF DISPENSING MEDICAMENT | ASTRAZENECA AB (SE) | 2010-04-15 | — | — | WO | disclosed |
| WO-2010042035-A1 | INHALER WITH INDEXING LINKED TO MOVEMENT OF COVER | ASTRAZENECA AB (SE) | 2010-04-15 | — | — | WO | disclosed |
| US-20100051027-A1 | Entraining Powder In An Airflow | ASTRAZENECA AB (SE) | 2010-03-04 | — | — | US | disclosed |
| US-20100029732-A1 | Combinations of Beta-2-Adrenoceptor Agonistic Benzothiazolone | ASTRAZENECA AB (SE) | 2010-02-04 | — | — | US | disclosed |
| WO-2009154562-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A 4-HYDROXY-2-OXO-2, 3- DIHYDRO-1, 3-BENZOTHIAZOL-7-YL COMPOUND FOR MODULATION OF BETA2-ADRENORECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2009-12-23 | — | — | WO | disclosed |
| WO-2009037503-A2 | NEW COMBINATION - 012 FOR THE TREATMENT OF RESPIRATORY DISEASES | ASTRAZENECA AB (SE) | 2009-03-26 | — | — | WO | disclosed |
| US-20080242649-A1 | New Combination 665 | ASTRAZENECA AB (SE) | 2008-10-02 | — | — | US | disclosed |
| US-20080220441-A1 | Advanced drug development and manufacturing | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242649-A1 | New Combination 665 | NR3C2, PTGER2, GRK5 | PTGS1 42/4885GSTK1 163/4885GLO1 2444/4885 |
| US-20100029732-A1 | Combinations of Beta-2-Adrenoceptor Agonistic Benzothiazolone | NR3C2, NR3C1, ARRB1 | PTGS1 37/4885GSTK1 116/4885GLO1 2364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.